Document Detail

Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study).
MedLine Citation:
PMID:  20152247     Owner:  NLM     Status:  MEDLINE    
In patients with heart failure (HF), statin treatment might improve myocardial perfusion, but could also have detrimental effects on myocardial metabolism. A predefined substudy of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial sought to determine the effects of statin treatment on myocardial blood flow reserve and cardiac metabolism. Sixteen patients with HF (New York Heart Association class II or III) were randomized to rosuvastatin 10 mg/day (n = 8) or placebo treatment (n = 8). At baseline and after 6 months of treatment, nitrogen-13 ammonia at rest and after dipyridamole stress and 18-fluorodeoxyglucose positron emission tomography were performed. Rosuvastatin treatment significantly lowered total (-36%, p <0.01) and low-density lipoprotein (-47%, p <0.001) cholesterol and C-reactive protein levels (-36%, p <0.05). Myocardial perfusion reserve (ratio) changed from 1.64 +/- 0.90 to 1.30 +/- 0.37 in placebo-treated and from 1.51 +/- 0.18 to 1.55 +/- 0.34 in rosuvastatin-treated patients (p = NS). Metabolic mismatch changed from 4.25 +/- 2.37% to 4.38 +/- 3.81% in placebo-treated and from 5.13 +/- 2.75% to 3.50 +/- 2.73% in rosuvastatin-treated patients (p = NS). In conclusion, changes regarding myocardial perfusion and metabolic mismatch after 6 months of rosuvastatin treatment in patients with HF did not suggest any beneficial or adverse effects in this pilot study, although due to the small numbers of patients small effects might have been missed.
Pim van der Harst; Riemer H J A Slart; Rene A Tio; Peter H J M Dunselman; Antoon T M Willemsen; Ad F M van den Heuvel; Adriaan A Voors; Dirk J van Veldhuisen;
Related Documents :
12626307 - The association of plasma homocysteine, coronary risk factors and serum nitrite in pati...
15604317 - Statins for heart failure: at the crossroads between cholesterol reduction and pleiotro...
9148647 - Clarifying the direct relation between total cholesterol levels and death from coronary...
2180267 - Hydroxymethylglutaryl coenzyme a reductase inhibitors as monotherapy in the treatment o...
18220897 - Cell based approaches for myocardial regeneration and artificial myocardium.
10362187 - Clinical validation of intravascular ultrasound imaging for assessment of coronary sten...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-01-05
Journal Detail:
Title:  The American journal of cardiology     Volume:  105     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-15     Completed Date:  2010-03-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  517-21     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Biological Markers / blood
C-Reactive Protein / biosynthesis
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Coronary Circulation / drug effects*
Dipyridamole / diagnostic use
Exercise Test
Fluorobenzenes / therapeutic use*
Fluorodeoxyglucose F18 / diagnostic use
Heart Failure / blood,  drug therapy*,  physiopathology*,  radionuclide imaging
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Lipoproteins / blood,  drug effects
Myocardium / metabolism*
Pilot Projects
Pyrimidines / therapeutic use*
Radiopharmaceuticals / diagnostic use
Sulfonamides / therapeutic use*
Tomography, Emission-Computed
Vasodilator Agents / diagnostic use
Reg. No./Substance:
0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoproteins; 0/Pyrimidines; 0/Radiopharmaceuticals; 0/Sulfonamides; 0/Vasodilator Agents; 287714-41-4/rosuvastatin; 58-32-2/Dipyridamole; 63503-12-8/Fluorodeoxyglucose F18; 9007-41-4/C-Reactive Protein
J Kjekshus / ; E Apetrei / ; V Barrios / ; M Bohm / ; J G Cleland / ; J H Cornel / ; P Dunselman / ; C Fonseca / ; A Goudev / ; P Grande / ; L Gullestad / ; A Hjalmarson / ; J Hradec / ; A Janosi / ; G Kamensky / ; M Komajda / ; J Korewicki / ; T Kuusi / ; F Mach / ; V Mareev / ; J J McMurray / ; N Ranjith / ; M Schaufelberger / ; J Vanhaecke / ; D J van Veldhuisen / ; F Waagstein / ; H Wedel / ; J Wikstrand /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of right ventricular function and venous congestion on cardiorenal interactions during the tr...
Next Document:  Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy.